Changes in bradykinin and prostaglandins plasma levels during dextran-sulfate low-density-lipoprotein apheresis

International Journal of Artificial Organs

Volumn 20, Issue 3, 1997, Pages 178-183

  Kojima, S ^a   Ogi, M ^a   Yoshitomi, Y ^a   Kuramochi, M ^a   Ikeda, J ^b   Naganawa, M ^b   Hatakeyama, H ^b  

^a SHIZUOKA MEDICAL CENTER   (Japan)

^b SRL INC   (Japan)

Author keywords

angiotensin converting enzyme; apheresis; bradykinin; dextran sulfate; endothelium derived relaxant factor; low density lipoprotein; plasma prekallikrein; prostaglandin

Indexed keywords

DEXTRAN; ENZYMES; LIPOPROTEINS;

ANGIOTENSIN-CONVERTING ENZYME; APHERESIS; BRADYKININ; DEXTRAN SULPHATE; ENDOTHELIUM-DERIVED RELAXANT FACTOR; GUANOSINES; LOW DENSITY LIPOPROTEINS; PLASMA KALLIKREIN; PLASMA LEVELS; PLASMA PREKALLIKREIN;

SULFUR COMPOUNDS;

BRADYKININ; DEXTRAN SULFATE; HEPARIN; LOW DENSITY LIPOPROTEIN; NAFAMSTAT MESILATE; PREKALLIKREIN; PROSTAGLANDIN;

ADULT; ANAPHYLAXIS; APHERESIS; ARTICLE; CASE REPORT; HUMAN; MALE; PLASMA;

EID: 0030916447     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139889702000310     Document Type: Article

References (20)

1. Kojima S, Harada-Shiba M, Nomura S, et al. Effect of nafamostat mesilate on bradykinin generation during low-density lipoprotein apheresis using a dextran sulfate cellulose column. Trans Am Soc Artif Intern Organs 1991; 37: 644-8.
2. McCarthy DA, Potter DE, Nicolaides ED. An in vivo estimation of the potencies and half-lives of synthetic bradykinin and kallidin. J Pharmacol Exp Ther 1965; 148: 117-22.
3. Olbricht CJ, Schaumann D, Fischer D. Anaphylactoid reactions, DS LDL apheresis with dextran sulphate, and ACE inhibitor. Lancet 1993; 341: 908-9.
4. Yang HYT, Erdos EG, Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta 1970; 214: 374-6.
5. Furchgott RF. The requirement of endothelial cells in the relaxation of the arteries by acetylcholine and some other vasodilators. Trends Pharmacol Sci 1981; 3: 175.
6. Toda N, Okamura T. Endothelium-dependent and -independent responses to vasoactive substances of isolated human coronary arteries. Am J Physiol 1989; 257: 988-95.
7. Murad F. Cyclic guanosine monophosphate as a mediator of vasodilatation. J Clin Invest 1986; 78: 1-5.
8. McGiff JC, Terragno NA, Malik KU, Lonigro AJ. Release of a prostaglandin E-like substance from canine kidney by bradykinin. Circ Res 1972; 31: 36-43.
9. Mullane KM, Moncada S. Prostacyclin mediates the potentiated hypotensive effect of bradykinin following captopril treatment. Eur J Pharmacol 1980; 66: 355-65.
10. Tani N. Development of selective adsorbent and DS LDL apheresis system: immobilized polyanions as LDL-specific adsorbent for DS LDL apheresis system. J Jpn Atheroscl Soc 1990; 18: 173-81.
11. Aoyama T, Ino Y, Ozeki M, et al. Pharmacological studies of FUT-175, nafamostat mesilate. Inhibitor of protenase activity in vitro and in vivo experiments. Jpn J Pharmacol 1984; 35: 203-27.
12. Shimamoto K, Ando T, Tanaka S, et al. An improved method for the determination of human blood kinin levels by sensitive kinin radioimmunoassay. Endocrinol Jpn 1982; 29: 487-94.
13. Powell WS. Rapid extraction of oxygenated metabolites of arachidonic acid from biological samples using octadecylsilyl silica. Prostaglandins 1980; 20: 947-57.
14. Honma M, Satoh T, Takezawa J, Ui M. An ultrasensitive method for the simultaneous determination of cyclic AMP and cyclic GMP in small-volume samples from blood and tissue. Biochem Med 1977; 18: 257-73.
15. Kojima S, Harada-Shiba M, Toyota Y, et al. Changes in coagulation factors by passage through a dextran sulfate column during low-density lipoprotein apheresis. Int J Artif Organs 1992, 15: 185-90.
16. Imanishi M, Ohta M, Kawamura M, et al. Aspirin test for differentiation of unilateral renovascular hypertension from hyperreninemic essential hypertension. Am J Hypertens 1991; 4: 761-8.
17. Davidson DC, Peart I, Turner S, Sangster M. Prevention with icatibant of anaphylactoid reactions to ACE inhibitor during DS LDL apheresis. Lancet 1994; 343: 1575.
18. Hamet P, Tremblay J, Pang SC, et al. Effect of native and synthetic atrial natriuretic factor on cyclic GMP. Biochem Biophys Res Commun 1984; 123: 515-27.
19. Kojima S, Karakawa S, Harada M, et al. Changes in plasma levels of atrial natriuretic peptide during plasmapheresis. Artificial Organs 1990; 14 (suppl 2): S188-91.
20. Kojima S, Shiba M, Kuramochi M, Yamamoto A. Effect of nafamostat mesilate on bradykinin generation and hemodynamics during DS LDL apheresis. Artificial Organs 1995; 19: 135-9.